PUBLISHER: Grand View Research | PRODUCT CODE: 1405747
PUBLISHER: Grand View Research | PRODUCT CODE: 1405747
U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share & Trends Analysis Report By Type (SPECT, PET), By PET Product (F-18, SR-82/RB-82), And Segment Forecasts, 2023 - 2030
U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Growth & Trends:
The U.S. prostate cancer nuclear medicine diagnostics market size is expected to reach USD 153.97 million by 2030, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 9.2% from 2023 to 2030. According to the American Cancer Society (ACS), in 2019, 174,650 new cases and 31,620 deaths caused by caused by prostate cancer are expected to be recorded in U.S. Such high prevalence of the disease is expected to drive the market growth.
Development of novel radiopharmaceuticals to improve the detection of the target disease is anticipated to accelerate the market growth. For instance, new imaging agents targeting Prostate-specific Membrane Antigen (PSMA) are being developed using 68Ga and 18F radioisotopes. In addition, numerous studies are being performed by researchers to develop new diagnostic agents for Positron Emission Tomography (PET) with higher efficiency as compared to the existing agents. For instance, 89Zr-huJ591 is an imaging agent used with PET for the detection of prostate cancer. This agent is in phase I/II of clinical trials, and is likely to get launched over the forecast period.
Growing demand for accurate diagnostic methods is estimated to fuel growth of the U.S. prostate cancer nuclear medicine diagnostics market. PET is commonly integrated with MRI and CT scan to enhance accuracy of diagnosis in malignancies. Therefore, researchers are conducting studies on PET/MRI to improve patient outcomes. For instance, in December 2018, a study was published in The Journal of Nuclear Medicine stating that 68Ga-PSMA-11 PET/MRI can be advantageous in detecting the target tumor.
Various non-profit organizations fund research studies to help introduce new imaging agents for the diagnosis of tumors. The Prostate Cancer Foundation is one of the major organizations that has been funding different studies for the development of PSMA-PET imaging for over 20 years. Presence of such funding organizations and programs is expected to boost the market growth during the forecast period.
Key market players have undertaken strategic initiatives to strengthen their market presence. For instance, in February 2018, Axumin (fluciclovine F 18) injection was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer. The updated guidelines used by clinicians and healthcare providers stated that fluciclovine F 18 for PET/MRI or PET/CT is considered in the clinical workup of patients with recurrent or advanced prostate cancer.
U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Report Highlights:
- In 2022, PET led the U.S. prostate cancer nuclear medicine diagnostics market owing to increased sensitivity and quantification of biochemical and physiological processes at a molecular level
- The SR-82/RB-82 segment is expected to expand at a CAGR of 9.9% over the forecast period
- Fluorine-18 led the PET products in 2022 owing to higher diagnostic performance and high-quality images, with a shorter acquisition time
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. PET product
- 1.1.3. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type
- 2.2.2. PET product
- 2.3. Competitive Insights
Chapter 3. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's Five Forces
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
- 3.4.1. Industry Analysis - Porter's Five Forces
Chapter 4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Estimates & Trend Analysis
- 4.1. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Key Takeaways
- 4.2. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Movement & Market Share Analysis, 2022 & 2030
- 4.3. SPECT
- 4.3.1. SPECT market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. PET
- 4.4.1. PET market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Estimates & Trend Analysis
- 5.1. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Key Takeaways
- 5.2. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Movement & Market Share Analysis, 2022 & 2030
- 5.3. F-18
- 5.3.1. F-18 market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. SR-82/RB-82
- 5.4.1. SR-82/RB-82 market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Others
- 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Recent Developments & Impact Analysis, By Key Participants
- 6.2. Company/Competition Categorization
- 6.2.1. Blue Earth Diagnostics
- 6.2.1.1. Company overview
- 6.2.1.2. Financial performance
- 6.2.1.3. Product benchmarking
- 6.2.1.4. Strategic initiatives
- 6.2.2. Siemens Healthcare Private Limited
- 6.2.2.1. Company overview
- 6.2.2.2. Financial performance
- 6.2.2.3. Product benchmarking
- 6.2.2.4. Strategic initiatives
- 6.2.3. Cardinal Health
- 6.2.3.1. Company overview
- 6.2.3.2. Financial performance
- 6.2.3.3. Product benchmarking
- 6.2.3.4. Strategic initiatives
- 6.2.4. CURIUM PHARMA
- 6.2.4.1. Company overview
- 6.2.4.2. Financial performance
- 6.2.4.3. Product benchmarking
- 6.2.4.4. Strategic initiatives
- 6.2.5. Lantheus
- 6.2.5.1. Company overview
- 6.2.5.2. Financial performance
- 6.2.5.3. Product benchmarking
- 6.2.5.4. Strategic initiatives
- 6.2.6. Jubilant Draximage Radiopharmacies, Inc.
- 6.2.6.1. Company overview
- 6.2.6.2. Financial performance
- 6.2.6.3. Product benchmarking
- 6.2.6.4. Strategic initiatives
- 6.2.7. NCM-USA LLC
- 6.2.7.1. Company overview
- 6.2.7.2. Financial performance
- 6.2.7.3. Product benchmarking
- 6.2.7.4. Strategic initiatives
- 6.2.8. Telix Pharmaceuticals Limited
- 6.2.8.1. Company overview
- 6.2.8.2. Financial performance
- 6.2.8.3. Product benchmarking
- 6.2.8.4. Strategic initiatives
- 6.2.9. ARICEUM THERAPEUTICS
- 6.2.9.1. Company overview
- 6.2.9.2. Financial performance
- 6.2.9.3. Product benchmarking
- 6.2.9.4. Strategic initiatives
- 6.2.10. Novartis AG
- 6.2.10.1. Company overview
- 6.2.10.2. Financial performance
- 6.2.10.3. Product benchmarking
- 6.2.10.4. Strategic initiatives
- 6.2.11. Life Molecular Imaging
- 6.2.11.1. Company overview
- 6.2.11.2. Financial performance
- 6.2.11.3. Product benchmarking
- 6.2.11.4. Strategic initiatives
- 6.2.1. Blue Earth Diagnostics
List of Tables
- Table 1 List of Abbreviations
- Table 2 U.S. prostate cancer nuclear medicine diagnostics market, by type, 2018 - 2030 (USD Million)
- Table 3 U.S. prostate cancer nuclear medicine diagnostics market, by PET product, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 QFD modeling for market share assessment
- Fig. 6 Market formulation & validation
- Fig. 7 U.S. prostate cancer nuclear medicine diagnostics: market outlook
- Fig. 8 U.S. prostate cancer nuclear medicine diagnostics market: competitive insights
- Fig. 9 Parent market outlook
- Fig. 10 Related/ancillary market outlook
- Fig. 11 Penetration and growth prospect mapping
- Fig. 12 U.S. prostate cancer nuclear medicine diagnostics market driver impact
- Fig. 13 U.S. prostate cancer nuclear medicine diagnostics market restraint impact
- Fig. 14 U.S. prostate cancer nuclear medicine diagnostics market strategic initiatives analysis
- Fig. 15 U.S. prostate cancer nuclear medicine diagnostics market: Type movement analysis
- Fig. 16 U.S. prostate cancer nuclear medicine diagnostics market: Type outlook and key takeaways
- Fig. 17 SPECT market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 18 PET market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 19 U.S. prostate cancer nuclear medicine diagnostics market: PET product movement analysis
- Fig. 20 U.S. prostate cancer nuclear medicine diagnostics market: PET product outlook and key takeaways
- Fig. 21 F-18 market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 22 SR-82/RB-82 market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 24 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
